Pathophysiology and clinical management of diabetes and prediabetes

Nutritional Strategies for the Diabetic and Prediabetic Patient

Volumn , Issue , 2006, Pages 15-44

  Rayfield, Elliot J ^a   Valentine, Marilyn V ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37349115608     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (119)

1. World Health Organization, Diabetes: The Cost of Diabetes. http://www.who.int/mediacentre/factsheets/fs236/en/, Accessed on December 5, 2004.
2. Centers for Disease Control and Prevention, Prevalence of diabetes and impaired fasting glucose in adults—United States, 1999-2000, MMWR, 52:833-837, 2003, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5235a1.htm, Accessed on January 22, 2005.
3. Kuzuya T, Nakagawa S, and Satoh J, et al., Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus, Diabetes Res Clin Pract, 55:65-85, 2002.
4. Diagnosis and Classification of Diabetes Mellitus, Diabetes Care, 27(Suppl 1):S5-10, 2004.
5. Awata T, Guberski DL, and Like AA, Genetics of the BB rat: Association of autoimmune disorders (diabetes, insulitis, and thyroiditis) with lymphopenia and major histocompatibility complex class II, Endocrinology, 136: 5731-5735, 1995.
6. Dahlquist G, Gustavsson KH, and Holmgren G et al., The incidence of diabetes mellitus in Swedish children 0-14 years of age, a prospective study 1977-1980, Acta Paediatr Scand, 71:7-14, 1982.
7. Eisenbarth GS, Type-1 diabetes mellitus: A chronic autoimmune disease, N Engl J Med, 314:1360-1368, 1986.
8. Khono T, Kobashiri Y, and Sugie Y et al., Antibodies to food antigens in Japanese patients with type-1 diabetes mellitus, Diabetes Res Clin Pract, 55:1-9, 2002.
9. Rayfield EJ and Ishimura K, Environmental factors and insulin-dependent diabetes mellitus, Diabetes Metab Rev, 3:925-957, 1987.
10. American Diabetes Association, Screening for type-2 diabetes, Diabetes Care, 27(Suppl 1):S11-14, 2004.
11. Pirola L, Johnson AM, and Van Obberghen E, Modulators of insulin action and their role in insulin resistance, Diabetologia, 47:170-184, 2004.
12. Kahn CR, Bruning JC, and Michael MD et al., Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes mellitus, J Pediatr Endocrinol Metab, 13:1377-1384, 2000.
13. Arner P, Pollare T, and Lithell H et al., Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type-2 diabetes mellitus, Diabetologia, 30:437-440, 1987.
14. Le Marchand-Brustel Y, Gremeaux T, and Ballotti R et al., Insulin receptor tyrosine kinase is defective in skeletal muscle of insulin-resistant obese mice, Natural, 315:676-679, 1985.
15. Li S, Covino ND, and Stein EG et al., Structural and biochemical evidence for an autoinhibitory role for tyrosine 984 in the juxtamembrane region of the insulin receptor, J Biol Chem, 278:26007-26014, 2003.
16. Sesti G, Federici M, and Lauro D et al., Molecular mechanism of insulin resistance in type-2 diabetes mellitus: Role of the insulin receptor variant forms, Diabetes Metab Res Rev, 17:363-373, 2001.
17. Petersen KF, Dufour S, and Befroy D et al., Impaired mitochondrial activity in the insulin-resistant offspring of patients with type-2 diabetes, N Engl J Med, 350:664-671, 2004.
18. Ganda OP, Secondary forms of diabetes, In: Kahn CR and Weir GC, Eds., Joslin’s Diabetes Mellitus, 13th ed., Lea and Febinger, Philadelphia, 1994, Table 17-1.
19. Mora PF, Post-transplantation diabetes mellitus, Am J Med Sci, 329:86-94, 2005.
20. Uchizono Y, Iwase M, and Nakamura U et al., Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling, Endocrinology, 145:2264-2272, 2004.
21. Backman LA, Post-transplant diabetes mellitus: The last 10 years with tacrolimus, Nephrol Dial Transplant, 19(Suppl 6):vi13-16, 2004.
22. Romagnoli J, Citterio F, and Violi P et al., Post-transplant diabetes mellitus: A case control analysis of the risk factors, Transplant Int, 18:309-312, 2005.
23. Luther P and Baldwin D, Jr, Pioglitazone in the management of diabetes mellitus after transplantation, Am J Transplant, 4:2135-2138, 2004.
24. American Diabetes Association, Gestational diabetes mellitus, Diabetes Care, 27(Suppl 1):S88-93, 2004.
25. Woo KS, Chook P, and Yu CW et al., Effects of diet and exercise on obesity-related vascular dysfunction in children, Circulation, 27:1981-1986, 2004.
26. Elliott BD, Langer O, and Schenker S et al., Insignificant transfer of glyburide occurs across the human placenta, Am J Obstet Gynecol, 165:807-812, 1991.
27. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Followup report on the diagnosis of diabetes mellitus, Diabetes Care, 26:3160-3167, 2003.
28. DECODE Study Group, the European Diabetes Epidemiology Group, Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria, Arch Intern Med, 161:397-405, 2001.
29. Sinha R, Fisch G, and Teague B, et al., Prevalence of impaired glucose tolerance among children and adolescents with marked obesity, J Clin Endocrinol Metab, 346:802-810, 2002.
30. Knowler WC, Barrett-Connor E, and Fowler SE et al., Diabetes Prevention Program Research Group, Reduction in the incidence of type-2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346:393-403, 2002.
31. Ruderman NB, Aoki TT, and Cahill GF, Jr, Gluconeogenesis and its disorders in man, In: Hansom RW and Mehlman MA, Eds., Gluconeogenesis: Its Regulation in Mammalian Species, New York: John Wiley and Sons 515-532, 1976.
32. Dinneen S, Gerich J, and Rizza R, Carbohydrate metabolism in non-insulin dependent diabetes mellitus, N Engl J Med, 327:707-713, 1992.
33. Pirola L, Johnston AM, and Obberghen EV, Modulation of insulin action, Diabetologia, 47:170-184, 2004.
34. Bickel PE, Lipid rafts and insulin signaling, Am J Physiol Endocrinol Metab, 282:E1-E10, 2002.
35. Montminy M and Koo SH, Outfoxing insulin resistance? Natural, 432:958-9, 2004.
36. Wolfrum C, Asilmaz E, and Luca E et al., Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes, Natural, 432:1027-1032, 2004.
37. Zong H, Ren JM, and Young LH et al., AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation, Proc Natl Acad Sci USA, 99:15983-15987, 2002.
38. Marik PE and Raghavan M, Stress-hyperglycemia, insulin and immunomodulation in sepsis, Intens Care Med, 30:748-756, 2004.
39. Lempaiainen P, Mykkanen L, and Pyorala K et al., Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men, Circulation, 100:123-128, 1999.
40. Collins AR, Pleiotropic vascular effects of PPAR-ligands, Drug News Perspectives, 2003, May, 16 (4):197-204, http://www.prous.com/journals/dnp/20031604/summary/dn0197.cfm, Accessed on July 2, 2005.
41. Klein JP and Waxman SG, The brain in diabetes: Molecular changes in neurons and their implications for end-organ damage, Lancet Neurol, 2:548-554, 2003.
42. Wu L, Nicholson W, and Knobel S et al., Oxidative stress is a mediator of glucose toxicity in insulinsecreting pancreatic islet cell lines, J Biol Chem, 279:12126-12134, 2004.
43. Robertson R, Harmon J, and Tran P et al., β-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type-2 diabetes, Diabetes, 53:S119-S124, 2004.
44. Robertson P, Harmon J, and Tran P et al., Glucose toxicity in β-cells: Type-2 diabetes, good radicals gone bad, and the glutathione connection, Diabetes, 52:581-587, 2003.
45. Nishkawa T, Edelstein D, and Liang Du X et al., Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage, Natural, 404:787-790, 2000.
46. Du X, Matsumura T, and Edelstein D et al., Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells, J Clin Invest, 112:1049-57, 2003.
47. Tanaka Y, Gleason C, and Tran P et al., Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants, Proc Natl Acad Sci USA, 96:10857-10862, 1999.
48. Rubio AR and Morales-Segura MA, Nitric oxide, an iceberg in cardiovascular physiology: Far beyond vessel tone control, Arch Med Res, 35:1-11, 2004.
49. Vane VR, Anggard EE, and Botting RM, Regulatory functions of the vascular endothelium, N Engl J Med, 323:27-36, 1990.
50. Libby P, Ridker M, and Maseri A, Inflammation and atherosclerosis, Circulation, 105:1135-1143, 2002.
51. Libby P, Inflammation in atherosclerosis, Natural, 420:868-874, 2002.
52. Ridker PM, Rifai N, and Rose L et al., Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events, N Engl J Med, 347:1557-1565, 2002.
53. Haffner S, Temprosa M, and Crandall J et al., Diabetes Prevention Program Research Group, Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance, Diabetes, 54:1566-1572, 2005.
54. Nicklas BJ, Ambrosius W, and Messier SP et al., Diet-induced weight loss, exercise, and chronic inflammation in older obese adults, Am J Clin Nutr, 79:544-551, 2004.
55. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329:977-986, 1993.
56. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33), Lancet, 352:837-853, 1998.
57. Wautier JL and Guillausseau PJ, Advanced glycation end products, their receptors, and diabetic angiopathy, Diabetes Metab (Paris), 27:535-542, 2001.
58. Ceriello A, New insights on oxidative stress and diabetic complications may lead to a ‘causal’ antioxidant therapy, Diabetes Care, 26:1589-1596, 2003.
59. Srivastava SK, Ramana KV, and Bhatnagar A, Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options, Endocr Rev, 10:1210/er.2004-0028 [Epub ahead of print], 2005 as doi (Endocr Rev, 26(Suppl 3):380-392, 2005, May).
60. Obrosova IG, Pacher P, and Szabo C et al., Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications, Diabetes, 54:234-242, 2005.
61. Ramana KV, Friedrich B, and Tammali R et al., Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells, Diabetes, 54:818-829, 2005.
62. Sivenius K, Niskanen L, and Voutilainen-Kaunisto R et al., Aldose reductase gene polymorphisms and susceptibility to microvascular complications in type-2 diabetes, Diabetic Med, 21:1325-1333, 2004.
63. Bril V and Buchanan RA, Aldose reductase inhbition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy, Diabetes Care, 27:2369-2375, 2004.
64. Federici M, Menghini R, and Mauriello A et al., Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells, Circulation, 23:466-472, 2002.
65. Pang H, Amano S, and Inagaki Y et al., N-acetylglucosamine-phosphate mutase genotype and diabetic microvascular complications, Diabet Med, 20:419-420, 2003.
66. Clark RJ, McDonough PM, and Swanson E et al., Diabetes and the acccompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation, J Biol Chem, 278:44230-44237, 2003.
67. Scoggie DA, Albright A, and Harris MD, The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type-2 diabetes mellitus: A placebo-controlled, doubleblinded, randomized clinical trial, Arch Int Med, 163:1587-1590, 2003.
68. Vlassara H, Brownlee M, and Cerami A, Nonenzymatic glycosylation: Role in the pathogenesis of diabetic complications, Clin Chem, 32(Suppl 10):B37-41, 1986.
69. Zieman SJ and Kass DA, Advanced glycation endproduct crosslinking in the cardiovascular system: Potential therapeutic target for cardiovascular disease, Drugs, 64:459-470, 2004.
70. Ahmed N, Advanced glycation endproducts-role in pathology of diabetic complications, Diabetes Res Clin Pract, 67:3-21, 2005.
71. Vlassara H, Cai W, and Crandall J et al., Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy, Proc Natl Acad Sci, 99:15596-15601, 2002.
72. Nandhini AT, Thisunavukkarasu V, and Anuradha CV, Stimulation of glucose utilization and inhibition of protein glycation and AGE products by taurine, Acta Physiol Scand, 181:297-303, 2004.
73. Way KJ, Katai N, and King GL, Protein kinase C and the development of diabetic vascular complications, Diabetic Med, 18:945-959, 2001.
74. Shen GX, Selective protein kinase C inhibitors and their applications, Curr Drug Targets Cardiovasc Haematol Disord, 3:301-307, 2003.
75. Rong J, Qiu H, and Wang S, Advanced glycosylation end products, protein kinase C and renal alterations in diabetic rats, Chin Med J, 113:1087-1091, 2000.
76. Aronson D and Rayfield EJ, How hyperglycemia promotes atherosclerosis: Molecular mechanisms, Cardiovasc Diabetol, 1:1-10, 2002.
77. American Diabetes Association Consensus Statement, Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes, Diabetes Care, 16:72-78, 1993.
78. Stamler J, Vaccaro O, and Neaton JD et al., Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial, Diabetes Care, 16:434-444, 1993.
79. Schwartz CJ, Valente AJ, and Sprague EA et al., Pathogenesis of the atherosclerotic lesion, Implications for diabetes mellitus, Diabetes Care, 15:1156-1167, 1992.
80. Caselli A, Rich J, and Hanane T et al., Role of C-nociceptive fibers in the nerve axon reflex-related vasodilatation in diabetes, Neurol, 60:297-300, 2003.
81. Veves A, Akbari C, and Primavera J et al., Endothelial dysfunction and the expression of endothelial nitric oxide synthase in diabetic neuropathy, vascular disease, and foot ulceration, Diabetes, 47:457-463, 1998.
82. Riddle MC, Rosenstock J, and Gerich J, Insulin Glargine 4002 Study Investigators, The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type-2 diabetic patients, Diabetes Care, 26:3080-3086, 2003.
83. van den Berghe G, Wouters P, and Weekers F et al., Intensive insulin therapy in the critically ill patient, N Engl J Med, 345:1359-1367, 2001.
84. Clemente S, Braithwaite SS, and Magee MF et al., American Diabetes Association Diabetes in Hospitals Writing Committee, Management of diabetes and hyperglycemia in hospitals, Diabetes Care, 27:553-561, 2004, Erratum in: Diabetes Care, 27:856, 2004, Hirsh Irl B [corrected to Hirsch Irl B]; dosage error in text, Diabetes Care, 27:1255, 2004, May.
85. AACE, Position statement on inpatient diabetes and metabolic control, Endocr Pract, 10:77-82, 2004.
86. Weissberg-Benchell J, Antisdel-Lomaglio J, and Seshadri R, Insulin pump therapy: A meta-analysis, Diabetes Care, 26:1079-1087, 2003.
87. Bode BW, Tamborlane W, and Davidson PC, Insulin pump therapy in the 21st century, Postgrad Med, 111:69-77, 2002.
88. Zavalkoff S and Polychronakos C, Evaluation of conventional blood glucose monitoring as an indicator of glucose values using a continuous subcutaneous sensor, Diabetes Care, 25:1603-1606, 2002.
89. Larsen J, Ford T, and Lyden E et al., What is hypoglycemia in patients with well-controlled type-1 diabetes treated by subcutaneous insulin pump with use of the continuous glucose monitoring system? Endocr Pract, 10:324-329, 2004.
90. Yki-Jarvinem H, Thiazolidenediones, N Engl J Med, 351:1106-1118, 2004.
91. Willson TM, Lambert MH, and Kliewer SA, Peroxisome proliferator-activated receptor γ and metabolic disease, Annu Rev Biochem, 70:341-367, 2001.
92. Chinetti B, Fruchart JC, and Staels B, Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation, Inflamm Res, 49:497-505, 2000.
93. Blanquart C, Mansouri R, and Paumelle R et al., The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferatoractivated receptor α, Mol Endocrinol, 18:1906-1918, 2004.
94. Barbier O, Torra IP, and Duquay Y et al., Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis, Arterioscler Thromb Vasc Biol, 22:717-726, 2002.
95. Nolan JJ, Ludvik B, and Beerdsen P et al., Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone, N Engl J Med, 331:1188-1193, 1994.
96. Miyazaki Y, Glass L, and Triplitt C et al., Effect of rosiglitazone on glucose and nonesterified fatty acid metabolism in type-2 diabetic patients, Diabetologia, 44:2210-2209, 2001.
97. Lubber WH, Potential role of oral thiazoladinedione therapy in preserving β-cell function in type-2 diabetes mellitus, Drugs, 65:1-13, 2005.
98. Buchanan TA, Xiang AH, and Peters RK et al., Preservation of pancreatic β-cell function and prevention of type-2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women, Diabetes, 51:2796-2803, 2002.
99. Saad MF, Greco S, and Osei K et al., for the Ragaglitazar Dose-ranging Study Group, Ragaglitazar improves glycemic control and lipid profile in type-2 diabetic subjects: A 12-week, double-blind, placebo-controlled, dose-ranging study with an open pioglitazone arm, Diabetes Care, 27:1324-1329, 2004.
100. Gribble FM and Reimann F, Differential selectivity of insulin secretagogues, Mechanisms, clinical implications, and drug interactions, J Diabetes Compl, 17:11-15, 2003.
101. Proks P, Reimann F, and Green N et al., Sulfonylurea stimulation of insulin secretion, Diabetes, 51:S368-S376, 2002.
102. Barg S, Mechanisms of exocytosis in insulin-secreting β-cells and glucagon-secreting A-cells, Pharmacol Toxicol, 92:3-13, 2003.
103. Dornhorst A, Insulinotropic meglitinide analogues, Lancet, 358:1709-1716, 2001.
104. Schmid-Antomarchi H, De Weille J, and Fosset M et al., The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells, J Biol Chem, 262:15840-15844, 1987.
105. Chiasson JL, Josse RG, and Gomis R et al., STOP-NIDDM Trial Research Group, Lancet, 359:2072-2077, 2002.
106. Drucker DJ, Enhancing insulin action for the treatment of type-2 diabetes, Diabetes Care, 26:2929-2940, 2003.
107. Drucker DJ, Biological actions and therapeutic potential of the glucagon-like peptides, Gastroenterol, 122:531-544, 2002.
108. Ebinger M, Jehle D, and Fussgaenger R et al., Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes, Am J Physiol Endocrinol Metab, 279:E88-E94, 2000.
109. Zander M, Christensen A, and Madsbad S et al., Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type-2 diabetes, Diabetes Care, 27:1910-1914, 2004.
110. D’Alessio DA and Vahl TP, Glucagon-like peptide 1: Evolution of an incretin into a treatment for diabetes, Am J Physiol Endocrinol Metab, 286:E882-E890, 2004.
111. Green BD, Gault VA, and O’harte FP et al., Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents, Curr Pharm Des, 10:3651-3662, 2004.
112. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329:977-986, 1993.
113. Leiter LA, Diabetic dyslipidaemia: Effective management reduces cardiovascular risk, Atheroscler Suppl, 6:37-43, 2005.
114. Gruessner AC and Sutherland DE, Pancreas transplant outcomes for United States (U.S.) and non-U.S. cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of May 2003, Clin Transplant, 21-51, 2003.
115. Shapiro AM, Lakey JR, and Ryan EA et al., Islet transplantation in seven patients with type-1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen, N Engl J Med, 343:230-238, 2000.
116. Tian C, Bagley J, and Cretin N et al., Prevention of type-1 diabetes by gene therapy, J Clin Immunol, 114:969-978, 2004.
117. Creusot RJ and Fathman CG, Gene therapy for type-1 diabetes: A novel approach for targeted treatment of autoimmunity, J Clin Invest, 114:892-894, 2004.
118. Adams G, Vessillier S, and Dreja H et al., Targeting cytokines to inflammation sites, Natural Biotechnol, 21:1314-1320, 2003.
119. Renard E, Implantable closed-loop glucose-sensing and insulin delivery: The future for insulin pump therapy, Curr Op Pharmacol, 2:708-716, 2002.